News

ProJect Pharmaceutics is a contract research and development organization (CRO) specialized in formulation and process development for parenteral drug products. Expanding the offering of its service portfolio towards the French customer base, ProJect Pharmaceutics was engaged to apply at the French Ministère de L’Enseignement Supérieur, De La Recherche Et De L’Innovation for eligibility to join

ProJect Pharmaceutics was granted a US patent on a novel formulation which effectively stabilizes the anti-cancer drug Bendamustine and other N-mustard cancer drugs like Chlorambucil, Melphalan, Melflufen, etc. in liquid state at room temperature for up to 24 months. LIQUID PHARMACEUTICAL FORMULATION US-Patent No: 11,752,135 US-Application No: 17/042,795 Contact us for: – Details of the

Are you looking for a CRO that quantifies the excipients in your formulation? Particularly for high concentrated protein formulations, a deep understanding of the Donnan effect in your specific formulation is of significant importance. We at ProJect Pharmaceutics have at your disposal the expertise, as well as state-of-the art chromatographic and spectroscopic analysis methods, for

ProJect Pharmaceutics is a contract research and development organization (CRO) specialized in formulation and process development for parenteral drug products. To support our client base and next generation customers alongside their formulation development needs, the company does posts on LinkedIn on a regular basis highlighting i.e. common problems we solve for our clients, tips and

Do you know the molar extinction coefficient of your (biologics) drug product? According to ICHQ6 the molar extinction coefficient needs to be experimentally determined for drug products. Here at ProJect Pharmaceutics, we are able to determine the extinction coefficient experimentally using an absolute gravimetric determination approach. Thereby we are able to consider not only the

ProJect Pharmaceutics is proud to have contributed with its services, expertise and knowledge to develop a lyophilized i.v. injection formulation for one of its clients’ drug products which was approved by the U.S. Food and Drug Administration (FDA). Goal of the development was to move from an oral administration of the drug to an injectable